In December 2023, the Californian company announced $32 million in Series A funding, led by Merck Global Health Innovation Fund (MGHIF) and TechBio-focused ARTIS Ventures. A month later, it announced a collaboration with Merck to apply Unnatural's technology to design and develop macrocyclic candidates against an oncology therapeutic target.